Continuous versus intermittent oral therapy with estramustine phosphate (Estracyt).
A preliminary report is presented of prospective, randomized study with continuous and intermittent oral Estracyt treatment in patients with prostatic carcinoma. It seems that the therapeutic effect of intermittent treatment is as favorable as continuous therapy. Side effects and costs are lower with intermittent therapy.